1 unchanged sentence
Rule 10b5 - 1 Trading Plans
−Removed: During the fiscal quarter ended March 31, 2026 , none of the Company's directors or executive officers adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5 - 1 (c) or any "non-Rule 10b5 - 1 trading arrangement."
+Added: During the fiscal quarter ended June 30, 2026 , none of the Company's directors or executive officers adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5 - 1 (c) or any "non-Rule 10b5 - 1 trading arrangement."
The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.
8 unchanged sentences
Amended and Restated Bylaws.
−Removed: Membership Interest Purchase Agreement between Inbox Pal, LLC and InsurCo, LLC, dated January 31, 2026
+Added: Form of Restricted Stock Unit Award Grant Notice (2022 Omnibus Equity Incentive Plan)
+Added: Amendment No.
+Added: 2 to Fluent, Inc.
+Added: 2022 Omnibus Equity Incentive Plan
+Added: + Management contract or compensatory plan or arrangement
Certification of Chief Executive Officer filed pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a) of the Securities and Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
14 unchanged sentences
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
+Added: August 13, 2026
/s/ Ryan Perfit
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.